Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
NCT ID: NCT03149523
Last Updated: 2017-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2017-05-31
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To date, there are few studies that combine a deep genomic characterization of both tumor and tumor microenvironment of the patient. Combining the two types of studies on the same tumor should help to define new therapeutic targets and should allow a combination of targeted and immunomodulatory therapies. To this end, our project is to conduct an exhaustive integrated exploratory analysis at genomic, transcriptomic and immunological levels of 3 tumor types (in colon, kidney and liver cancer).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
NCT03364621
Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer
NCT02838381
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
NCT05787197
Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.
NCT06929013
Next Generation " Pre-clinical Model for Colorectal Cancer Metastases and Hepatocellular Carcinomas
NCT05384184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The tumor samples will be taken during surgery. Blood and tumors samples will be taken as part of the treatment.
In case of a accidental germline discovery a management by a genetic consulting will be proposed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Colorectal cancer
Patient with stage III colon carcinoma
No interventions assigned to this group
Kidney cancer
Patient with clear cell kidney carcinoma more than 4 cm surgically removed
No interventions assigned to this group
Liver cancer
Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* for kidney cancer group : patient with primary clear cell carcinoma more than 4 cm
* for liver cancer group : patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C
* patients who have consented to the study
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
European Georges Pompidou Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pierre Laurent-Puig
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AP-HP Jean Verdier Hospital
Bondy, , France
AP-HP Cochin Hospital
Paris, , France
AP-HP European Georges Pompidou Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CARPEM_ExhauCRF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.